Get the Latest Social Media Buzz from #ASCO24! Follow what the KOLSs are tweeting This account is not associated with the American Society of Clinical Oncology.
Joined May 2022
- Tweets376
- Following731
- Followers195
- Likes13
ASCO23 Flashback: Dr. Prasad's Video Criticisms of ADAURA #asco25 hubs.ly/Q03mgy7d0
The UK Just Approved Blenrep for Relapsed/Refractory Multiple Myeloma, What do Top KOLs think? #mmsm hubs.ly/Q03j7YWz0 KOL Tweets from :
Exciting Uromigos Podcast discussion of ivonescimab for NSCLC by Dr. John Heymach.
Check out the highlights👉Is Ivonescimab Too Good To Be True? Highlights of Dr. John Heymach's Uromigos Podcast hubs.ly/Q03dFDfY0
🚀 Dive into the future of Oncology Journal Clubs with AI!
Discover insights from key opinion leaders (KOLs) on the HARMONi-2 Journal Club AI Co-Pilot.
Ready to explore? 🌟🔍 #ClinicalTrials #Innovation #HARMONi-2 hubs.ly/Q039-FWP0
ASCO BUZZ retweeted
#Myeloma Paper of the Day: Study of most common symptomatic adverse reactions of cancer treatments from US drug labels (2015-2021) to inform selection of patient-reported outcomes finds cough was common (50%) in multiple myeloma: pubmed.ncbi.nlm.nih.gov/3938…. #mmsm
ASCO BUZZ retweeted
5yr outcomes Ph II NADIM trial:
- 5yr PFS 65% OS 69.3%
- pCR: 5yr PFS 92% OS 95.8%; nonpCR 60%&66%
- ctDNA clearance: 5yr PFS 85.2% OS 92.3%
‘pts disease-free beyond 3yrs, could be considered cured’
Powerful conclusion, powerful trial @MARIANOPROVENCI
thelancet.com/journals/lanon…
ASCO BUZZ retweeted
You know who you are, we all do.
☠️🤡👀 #MedTwitter
Don't let what you see on social media skew your view of humanity.
Most bad behavior is due to a few bad apples:
• Just 3% of active users are toxic, but they generate 33% of online content
• 1% of communities launch 74% of conflict
• 0.1% of users spread 80% of fake news
@jayvanbavel podcasts.apple.com/us/podcas…
ASCO BUZZ retweeted
🚨 BIG NEWS 🚨
Press Release: Addition of Lurbinectedin to Atezolizumab maintenance ➡️ Significant improvement in OS and PFS!
Phase 3 IMforte trial
ES-SCLC 1L maintenance
Atezo + lurbinectedin
⬆️PFS ✅
⬆️OS ✅
NDA➡️2025
#LCAM #SCLC @SclcSMASHERS
investor.jazzpharma.com/news…
The @US_FDA just granted approval to @SarclisaHCP from @SanofiUS based on the IMROZ clinical trial. Find out what thought leaders in myeloma think of this trial with this interactive AI Chatbot👉IMROZ AI Chatbot hubs.ly/Q02QG-Wv0 #mmsm #asco24 #medtwitter
The FDA just approved @SarclisaHCP quad therapy for newly diagnosed multiple myeloma. Read Key Opinion Leader Sentiment regarding this important trial. #mmsm #ASCO24 IMROZ Clinical Trial Sentiment hubs.ly/Q02QGr3P0
IMROZ Clinical Trial Sentiment hubs.ly/Q02QGZMC0 grants FDA Approval based on IMROZ clinical trial.
Read what Myeloma Experts think of this clinical trial by @sanofi
ASCO BUZZ retweeted
Kisqali is currently a blockbuster breast cancer medicine for @Novartis in late stage breast cancer.
Check out the wide range of physician opinions regarding the NATALEE trial studying Kisqali in early stage breast cancer. How will the FDA decide later this year on this potential new indication? #bcsm
👉beta.kolpulse.com/public/140…
CONTACT-02 was a major clinical trial presented at #ESMO24. KOL sentiments were all over the map for this trial. What did the KOLs say and how did their sentiments differ? Check it out with the use of Artificial Intelligence 👉CONTACT-02 AI Chatbot
kolpulse.com/contact-clinica…
KEYNOTE-522 Sentiment Analysis and Key Opinion Leader Discussion including #ESMO24👉KEYNOTE-522 Clinical Trial Sentiment hubs.ly/Q02PWXtN0
ASCO BUZZ retweeted
#ICYMI: The treatment landscape for patients with resectable NSCLC has changed!
My newly updated slide for our fellows. @OncoAlert #lcsm #WCLC24
@US_FDA approves perioperative durvalumab for resectable NSCLC
🌊 AEGEAN Ph 3:
▫️Stage IIA-IIIB NSCLC
▫️Durvalumab + chemo v placebo + chemo
▫️EFS: Not reached vs. 25.9 mos (HR 0.68)
▫️pCR: 17% v 4.3%
@OncoAlert fda.gov/drugs/resources-info…
Will Summit Therapeutics $SMMT HARMONI-2 Clinical Trial data displace @Merck Keytruda as the king of Lung Cancer Therapy? #WCLC24 Follow the interesting backstory on this Plenary Session topic for Sunday's Meeting. #LCSM
Are you prepared for the World Congress on Lung Cancer Meeting this weekend? Do you know the backstory of the plenary session HARMONI-2 clinical trial? Are the Robinhooders ready to go📈 $SMMT
👉The Wild West of World Lung Cancer #WCLC24 hubs.ly/Q02NY2tm0
ASCO BUZZ retweeted
Are you prepared for the World Congress on Lung Cancer Meeting this weekend? Do you know the backstory of the plenary session HARMONI-2 clinical trial? Are the Robinhooders ready to go📈 $SMMT
👉The Wild West of World Lung Cancer #WCLC24 hubs.ly/Q02NY2tm0
🔥 Hot takes on ADAURA Trial from #ASCO23 🎙️ADAURA Sentiment Analysis hubs.ly/Q02KHXh70💡Is it a game-changer or are we missing the mark? Dive into the debate & share your thoughts! 🧬💊 #oncology #medicalresearch #ASCO2023